Advertisement
Organisation › Details
InflaRx N.V. (Nasdaq Global Select Market: IFRX)
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover and develop first-in-class or best-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. Complement C5a and its receptor C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. The COVID-19 related work for vilobelimab was partly funded by the German federal government through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx. *
Start | 2017-06-01 established | |
Group | InflaRx (Group) | |
Industry | anti-inflammatory drug | |
Industry 2 | IFX-1 (InflaRx) | |
Person | Riedemann, Niels C. (InflaRx 200803 Managing Director + founder) | |
Person 2 | Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst) | |
Region | Amsterdam | |
Country | Netherlands | |
City | n. a. Amsterdam | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Profit | -53,254,817 (2019-12-31) | |
Cash | 115,485,147 (2019-03-31) | |
* Document for »About Section«: InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena. | ||
Record changed: 2024-02-23 |
Advertisement
More documents for InflaRx (Group)
- [1] InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena....
- [2] InflaRx N.V.. (1/25/24). "Press Release: InflaRx Announces Initiation of Its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients". Ann Arbor, MI....
- [3] InflaRx N.V.. (4/18/23). "Press Release: InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million". Jena....
- [4] InflaRx N.V.. (4/14/23). "Press Release: InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares". Jena....
- [5] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares". Jena....
- [6] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Public Offering of Ordinary Shares". Jena....
- [7] InflaRx N.V.. (4/4/23). "Press Release: InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients". Jena....
- [8] Immatics N.V.. (9/29/20). "Press Release: Immatics Appoints Arnd Christ as Chief Financial Officer". Tübingen & Houston, TX....
- [9] InflaRx N.V.. (9/17/20). "Press Release: InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer". Jena....
- [10] InflaRx N.V.. (3/31/20). "Press Release: InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology". Jena....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top